Old Web
English
Sign In
Acemap
>
authorDetail
>
Andres Schneider
Andres Schneider
Hoffmann-La Roche
Crenezumab
Disease
Medicine
Tolerability
Psychiatry
4
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A synthetic control arm from observational data to estimate the background incidence rate of an adverse event in patients with Alzheimer’s disease matched to a clinical trial population: Epidemiology / Innovative methods in epidemiology (i.e., assessment methods, design, recruitment strategies, statistical methods, etc.)
2020
Alzheimers & Dementia
Kathleen Blondeau
Andres Schneider
Innocent Ngwa
Show All
Source
Cite
Save
Citations (0)
Baseline Characteristics from a Phase III Trial of Crenezumab in Early (Prodromal-to-Mild) Alzheimer’s Disease (CREAD) (P4.1-002)
2019
Neurology
Kaycee M. Sink
Susanne Ostrowitzki
Laurie Millar
Francis Warren
Helen Lin
Jillian Smith
Andres Schneider
Reina N. Fuji
Angelica Quartino
Howard Mackey
Michael Rabbia
Susan Yule
Paulo Fontoura
Rachelle Doody
Show All
Source
Cite
Save
Citations (0)
BASELINE CHARACTERICS FROM A PHASE 3 TRIAL OF CRENEZUMAB IN PRODROMAL TO MILD ALZHEIMER’S DISEASE (CREAD)
2018
Alzheimers & Dementia
Helen Lin
Susanne Ostrowitzki
Kaycee M. Sink
Laurie Millar
Francis Warren
Jillian Smith
Andres Schneider
Reina N. Fuji
Angelica Quartino
Howard Mackey
Michael Rabbia
Susan Yule
Paulo Fontoura
Rachelle Doody
Show All
Source
Cite
Save
Citations (1)
Safety, Tolerability and Pharmacokinetics of Crenezumab in Mild-to-Moderate AD Patients Treated with Escalating Doses for up to 32.3 Months (P6.182)
2018
Neurology
H. Lin
Andres Schneider
Angelica Quartino
Tobias Bittner
Nan Hu
Jillian Smith
William Cho
Susanne Ostrowitzki
Show All
Source
Cite
Save
Citations (1)
1